Abbisko Medicine Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
286
- Stock Symbol
-
02256
- Investments
-
1
- Share Price
-
$0.87
- (As of Friday Closing)
Abbisko Medicine General Information
Description
Abbisko Medicine Co Ltd Formerly Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of medicines and differentiated small molecule oncology therapies. The company has pipeline of 21 program candidates, with a primary focus on oncology and pimicotinib has received approval from the China NMPA, and several other candidates are currently in clinical development stage. The company has only one business segment which is the development of medicines. Geographically, the company has it's concentration in European Union and Chinese mainland region.
Contact Information
Website
www.abbisko.comCorporate Office
- 12B Floor, Building 1, Lane 515, Huanke Road
- Pudong New Area
- Shanghai
- China
Corporate Office
- 12B Floor, Building 1, Lane 515, Huanke Road
- Pudong New Area
- Shanghai
- China
Abbisko Medicine Stock Performance
As of 13-Nov-2026, Abbisko Medicine’s stock price is $0.87. Its current market cap is $620M with 716M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.87 | $0.92 | $0.77 - $1.93 | $620M | 716M | 1.54M | -$0.11 |
Abbisko Medicine Financials Summary
As of 30-Jun-2026, Abbisko Medicine has a trailing 12-month revenue of $13.9M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 726,889 | 798,977 | 81,637 | 3,933 |
| Revenue | 13,900 | 85,119 | 70,238 | 2,694 |
| EBITDA | (74,668) | 6,841 | 1,966 | (67,349) |
| Net Income | (66,695) | 7,682 | 3,944 | (61,002) |
| Total Assets | 396,724 | 336,316 | 288,633 | 298,420 |
| Total Debt | 66,929 | 43,375 | 3,327 | 5,040 |
Abbisko Medicine Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Abbisko Medicine Comparisons
Industry
Financing
Details
Abbisko Medicine Competitors (17)
One of Abbisko Medicine’s 17 competitors is Alphamab Oncology, a Formerly VC-backed company based in Suzhou, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alphamab Oncology | Formerly VC-backed | Suzhou, China | ||||
| EMD Serono | Corporation | Boston, MA | ||||
| Grifols | Corporation | Barcelona, Spain | ||||
| BeOne Medicines | Formerly PE-Backed | Beijing, China | ||||
| Immatics | Formerly VC-backed | Tuebingen, Germany |
Abbisko Medicine Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Abbisko Medicine Patents
Abbisko Medicine Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026208480-A1 | Gipr antagonist and pharmaceutical use thereof | Pending | 03-Apr-2025 | ||
| WO-2026184698-A1 | Selective smarca2 degrader, and preparation therefor and use thereof | Pending | 07-Mar-2025 | ||
| WO-2026051764-A1 | Kras inhibitor containing n-n bond and pharmaceutical use thereof | Pending | 04-Sep-2024 | ||
| WO-2026040953-A1 | Polycyclic parg inhibitor and uses thereof | Pending | 19-Aug-2024 | ||
| WO-2026021459-A1 | Compound having kras inhibitory activity and pharmaceutical use thereof | Pending | 25-Jul-2024 |
Abbisko Medicine Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Abbisko Medicine Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Abbisko Medicine Investments (1)
Abbisko Medicine’s most recent deal was a Seed Round with Shanghai Enflame Tech. The deal was made on 01-Apr-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Shanghai Enflame Tech | 01-Apr-2018 | Seed Round | Application Specific Semiconductors |
Abbisko Medicine ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
41.54 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Abbisko Medicine Exits (1)
Abbisko Medicine’s most recent exit was on 01-Apr-2018 from Shanghai Enflame Tech. The exit was categorized as with 7 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Shanghai Enflame Tech | 01-Apr-2018 | Completed |
|
Abbisko Medicine FAQs
-
When was Abbisko Medicine founded?
Abbisko Medicine was founded in 2016.
-
Where is Abbisko Medicine headquartered?
Abbisko Medicine is headquartered in Shanghai, China.
-
What is the size of Abbisko Medicine?
Abbisko Medicine has 286 total employees.
-
What industry is Abbisko Medicine in?
Abbisko Medicine’s primary industry is Drug Discovery.
-
Is Abbisko Medicine a private or public company?
Abbisko Medicine is a Public company.
-
What is Abbisko Medicine’s stock symbol?
The ticker symbol for Abbisko Medicine is 02256.
-
What is the current stock price of Abbisko Medicine?
As of 13-Nov-2026 the stock price of Abbisko Medicine is $0.87.
-
What is the current market cap of Abbisko Medicine?
The current market capitalization of Abbisko Medicine is $620M.
-
What is Abbisko Medicine’s current revenue?
The trailing twelve month revenue for Abbisko Medicine is $13.9M.
-
Who are Abbisko Medicine’s competitors?
Alphamab Oncology, EMD Serono, Grifols, BeOne Medicines, and Immatics are some of the 17 competitors of Abbisko Medicine.
-
What is Abbisko Medicine’s annual earnings per share (EPS)?
Abbisko Medicine’s EPS for 12 months was -$0.11.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
